Pharm Exec: COVID-19: Unintended Consequences

The redirection of healthcare and life sciences resources to COVID-19 has taken focus from other areas of need, including antimicrobial resistance. It is not yet clear how COVID-19 will ultimately impact AMR. Early in the crisis, use of antibiotics, including azithromycin and ceftriaxone spiked, and 72% to 92% of patients received antibiotics despite there being no clear evidence that COVID-19 patients are more susceptible to bacterial infections than those with flu-like illnesses.